New tests launched in April - Insights
In April 2022, Mayo Clinic Laboratories announced fourteen new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
Assay stratifies pregnant women's preeclampsia risk: Joshua Bornhorst, Ph.D. - Insights
Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' unique assay identifies pregnant women at risk of developing preeclampsia with severe features. Test results can guide clinical management, to safeguard maternal and neonatal...
Communiqué Archives - Page 4 of 4 - Insights
Skip to Content MayoACCESS MayoLINK...
Antimicrobial Crisis: A Silent Threat Claiming Lives - Insights from Dr. Robin Patel - Insights
Globally, five million deaths are associated with bacterial antimicrobial resistance each year, but the complexity of the issue is there is no single solution because we need to use antibiotics. It’s about finding a different way to live...
New tests launched in July - Insights
In July 2022, Mayo Clinic Laboratories announced fifteen new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
Autoimmune Gastrointestinal Dysmotility Evaluation [Test in Focus] - Insights
Divyanshu (Div), Dubey, M.B.B.S, gives an overview of the new Autoimmune Gastrointestinal Dysmotility Evaluation available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing compares to...
Assay identifies patients eligible for new ovarian cancer drug: Maryam Shahi, M.D. - Insights
Maryam Shahi, M.D., explains how Mayo Clinic Laboratories' unique biomarker test (TEST ID: AFOLR) determines which patients would likely benefit from a new treatment for recurrent epithelial ovarian cancer. Disease recurrence is common, and...
Urinary Steroid Profile [Test in Focus] - Insights
Irina Bancos, M.D. gives an overview of this test available through Mayo Clinic Laboratories. She discusses when this testing should be ordered, how this testing compares to other testing approaches, and what clinical action can be taken...
Paul Jannetto, Ph.D., explains the advantages that Mayo Clinic Laboratories' oral fluid drug screening offers over typical urine tests. Oral samples are easier to collect and harder to adulterate.
Learn why liquid biopsy testing is a viable alternative to tissue-based biopsy testing for certain patients with cancer.